JP2025508316A5 - - Google Patents
Info
- Publication number
- JP2025508316A5 JP2025508316A5 JP2024543215A JP2024543215A JP2025508316A5 JP 2025508316 A5 JP2025508316 A5 JP 2025508316A5 JP 2024543215 A JP2024543215 A JP 2024543215A JP 2024543215 A JP2024543215 A JP 2024543215A JP 2025508316 A5 JP2025508316 A5 JP 2025508316A5
- Authority
- JP
- Japan
- Prior art keywords
- peptide linker
- fragment
- multispecific antibody
- antibody according
- her2
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2022073220 | 2022-01-21 | ||
| CNPCT/CN2022/073220 | 2022-01-21 | ||
| PCT/US2023/061051 WO2023141611A2 (en) | 2022-01-21 | 2023-01-20 | Multi-specific antibodies in uses thereof in avidity receptor crosslinking and immune modulation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025508316A JP2025508316A (ja) | 2025-03-26 |
| JP2025508316A5 true JP2025508316A5 (https=) | 2026-01-27 |
Family
ID=87349191
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024543215A Pending JP2025508316A (ja) | 2022-01-21 | 2023-01-20 | アビディティ受容体架橋及び免疫調節における使用における多重特異性抗体 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20250388669A1 (https=) |
| EP (1) | EP4466020A4 (https=) |
| JP (1) | JP2025508316A (https=) |
| CN (1) | CN119053342A (https=) |
| WO (1) | WO2023141611A2 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111201030B (zh) | 2017-07-25 | 2024-11-01 | 真和制药有限公司 | 通过阻断tim-3和其配体的相互作用治疗癌症 |
| WO2020160156A2 (en) | 2019-01-30 | 2020-08-06 | Immutics, Inc. | Anti-gal3 antibodies and uses thereof |
| EP4157338A4 (en) | 2020-05-26 | 2024-11-13 | TrueBinding, Inc. | METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING |
| IL326099A (en) * | 2023-07-26 | 2026-03-01 | Lyvgen Biopharma Holdings Ltd | Multispecific antibodies incorporating dual immunogenic control entities and their uses in immunotherapy |
| CN121843714A (zh) | 2023-08-11 | 2026-04-10 | 派拉冈医疗公司 | Tl1a结合抗体及使用方法 |
| TW202532431A (zh) * | 2023-09-21 | 2025-08-16 | 大陸商樂普創一生物科技（上海）有限公司 | 多特異性抗體及其用途 |
| CN119912577A (zh) * | 2023-10-31 | 2025-05-02 | 北京智仁美博生物科技有限公司 | 结合hla-a24/prame复合体的多种抗体及其用途 |
| WO2025157132A1 (en) * | 2024-01-23 | 2025-07-31 | Wuxi Biologics (Shanghai) Co., Ltd. | Multispecific antibodies targeting cd3, cd19 and cd20 and uses thereof |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2699596A4 (en) * | 2011-04-22 | 2015-01-14 | Emergent Product Dev Seattle | PROSTATE-SPECIFIC MEMBRANE-BINDING PROTEINS AND COMPOSITIONS AND METHOD THEREFOR |
| HRP20201370T1 (hr) * | 2011-11-07 | 2020-11-27 | Medimmune Limited | Kombinacijske terapije koje koriste anti-pseudomonas psl i pcrv vezujuće molekule |
| WO2015171504A1 (en) * | 2014-05-05 | 2015-11-12 | Medimmune, Llc | Multi-specific anti-pseudomonas psl and pcrv binding molecules and uses thereof |
| WO2017165464A1 (en) * | 2016-03-21 | 2017-09-28 | Elstar Therapeutics, Inc. | Multispecific and multifunctional molecules and uses thereof |
| SG11201909160WA (en) * | 2017-04-11 | 2019-10-30 | Inhibrx Inc | Multispecific polypeptide constructs having constrained cd3 binding and methods of using the same |
| KR20260046525A (ko) * | 2018-04-11 | 2026-04-07 | 인히브릭스 바이오사이언스, 인크. | 제한된 cd3 결합을 갖는 다중특이적 폴리펩티드 컨스트럭트 및 관련된 방법 및 용도 |
| CA3099450A1 (en) * | 2018-05-08 | 2019-11-14 | Amgen Inc. | Bispecific antibodies with cleavable c-terminal charge-paired tags |
| CA3108044A1 (en) * | 2018-07-31 | 2020-02-06 | Daiichi Sankyo Company, Limited | Treatment of metastatic brain tumor by administration of antibody-drug conjugate |
| US20230340157A1 (en) * | 2019-09-27 | 2023-10-26 | Beijing Starmab Biomed Technology Ltd | Monospecific and multi-specific antibodies |
-
2023
- 2023-01-20 US US18/730,415 patent/US20250388669A1/en active Pending
- 2023-01-20 EP EP23743980.7A patent/EP4466020A4/en active Pending
- 2023-01-20 JP JP2024543215A patent/JP2025508316A/ja active Pending
- 2023-01-20 CN CN202380028724.4A patent/CN119053342A/zh active Pending
- 2023-01-20 WO PCT/US2023/061051 patent/WO2023141611A2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025508316A5 (https=) | ||
| JP2024532485A5 (https=) | ||
| CN107922486B (zh) | 异源二聚体多特异性抗体形式 | |
| JP2021042257A5 (https=) | ||
| JP2021098732A5 (https=) | ||
| JP2022541435A5 (https=) | ||
| JP2025078629A5 (https=) | ||
| JP2022514693A5 (https=) | ||
| JP2022545647A5 (https=) | ||
| US12098203B2 (en) | Hetero-dimeric multi-specific antibody format targeting at least CD3 and HSA | |
| JP2019525738A5 (https=) | ||
| JP2017504578A5 (https=) | ||
| TWI874613B (zh) | 微型導引和導航控制(miniGNC)類抗體蛋白及其製造和使用方法 | |
| JP2020508334A5 (https=) | ||
| JP2023509212A5 (https=) | ||
| JP2021515798A5 (https=) | ||
| JP2017522891A5 (https=) | ||
| JP2022504826A5 (https=) | ||
| IL276903B1 (en) | Bispecific egfr/cd16 antigen-binding protein | |
| JP2023507729A5 (https=) | ||
| JP2023516004A5 (https=) | ||
| CN115066274A (zh) | 三价结合分子 | |
| JP2024508672A5 (https=) | ||
| JP2025508882A5 (https=) | ||
| JP2023537002A5 (https=) |